Serveur d'exploration MERS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Evaluation of phage display discovered peptides as ligands for prostate-specific membrane antigen (PSMA).

Identifieur interne : 001B48 ( PubMed/Checkpoint ); précédent : 001B47; suivant : 001B49

Evaluation of phage display discovered peptides as ligands for prostate-specific membrane antigen (PSMA).

Auteurs : Duanwen Shen [États-Unis] ; Fei Xie ; W Barry Edwards

Source :

RBID : pubmed:23935860

Descripteurs français

English descriptors

Abstract

The aim of this study was to identify potential ligands of PSMA suitable for further development as novel PSMA-targeted peptides using phage display technology. The human PSMA protein was immobilized as a target followed by incubation with a 15-mer phage display random peptide library. After one round of prescreening and two rounds of screening, high-stringency screening at the third round of panning was performed to identify the highest affinity binders. Phages which had a specific binding activity to PSMA in human prostate cancer cells were isolated and the DNA corresponding to the 15-mers were sequenced to provide three consensus sequences: GDHSPFT, SHFSVGS and EVPRLSLLAVFL as well as other sequences that did not display consensus. Two of the peptide sequences deduced from DNA sequencing of binding phages, SHSFSVGSGDHSPFT and GRFLTGGTGRLLRIS were labeled with 5-carboxyfluorescein and shown to bind and co-internalize with PSMA on human prostate cancer cells by fluorescence microscopy. The high stringency requirements yielded peptides with affinities KD~1 µM or greater which are suitable starting points for affinity maturation. While these values were less than anticipated, the high stringency did yield peptide sequences that apparently bound to different surfaces on PSMA. These peptide sequences could be the basis for further development of peptides for prostate cancer tumor imaging and therapy.

DOI: 10.1371/journal.pone.0068339
PubMed: 23935860


Affiliations:


Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:23935860

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Evaluation of phage display discovered peptides as ligands for prostate-specific membrane antigen (PSMA).</title>
<author>
<name sortKey="Shen, Duanwen" sort="Shen, Duanwen" uniqKey="Shen D" first="Duanwen" last="Shen">Duanwen Shen</name>
<affiliation wicri:level="2">
<nlm:affiliation>Radiology, Washington University, St Louis, Missouri, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Radiology, Washington University, St Louis, Missouri</wicri:regionArea>
<placeName>
<region type="state">Missouri (État)</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Xie, Fei" sort="Xie, Fei" uniqKey="Xie F" first="Fei" last="Xie">Fei Xie</name>
</author>
<author>
<name sortKey="Edwards, W Barry" sort="Edwards, W Barry" uniqKey="Edwards W" first="W Barry" last="Edwards">W Barry Edwards</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2013">2013</date>
<idno type="RBID">pubmed:23935860</idno>
<idno type="pmid">23935860</idno>
<idno type="doi">10.1371/journal.pone.0068339</idno>
<idno type="wicri:Area/PubMed/Corpus">001C24</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001C24</idno>
<idno type="wicri:Area/PubMed/Curation">001C24</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001C24</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001B48</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001B48</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Evaluation of phage display discovered peptides as ligands for prostate-specific membrane antigen (PSMA).</title>
<author>
<name sortKey="Shen, Duanwen" sort="Shen, Duanwen" uniqKey="Shen D" first="Duanwen" last="Shen">Duanwen Shen</name>
<affiliation wicri:level="2">
<nlm:affiliation>Radiology, Washington University, St Louis, Missouri, United States of America.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Radiology, Washington University, St Louis, Missouri</wicri:regionArea>
<placeName>
<region type="state">Missouri (État)</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Xie, Fei" sort="Xie, Fei" uniqKey="Xie F" first="Fei" last="Xie">Fei Xie</name>
</author>
<author>
<name sortKey="Edwards, W Barry" sort="Edwards, W Barry" uniqKey="Edwards W" first="W Barry" last="Edwards">W Barry Edwards</name>
</author>
</analytic>
<series>
<title level="j">PloS one</title>
<idno type="eISSN">1932-6203</idno>
<imprint>
<date when="2013" type="published">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Amino Acid Sequence</term>
<term>Binding Sites</term>
<term>Biomarkers, Tumor (chemistry)</term>
<term>Biomarkers, Tumor (genetics)</term>
<term>Biomarkers, Tumor (metabolism)</term>
<term>Cell Line, Tumor</term>
<term>Fluoresceins</term>
<term>Gene Expression</term>
<term>High-Throughput Screening Assays</term>
<term>Humans</term>
<term>Immobilized Proteins (chemistry)</term>
<term>Immobilized Proteins (genetics)</term>
<term>Immobilized Proteins (metabolism)</term>
<term>Kallikreins (chemistry)</term>
<term>Kallikreins (genetics)</term>
<term>Kallikreins (metabolism)</term>
<term>Ligands</term>
<term>Male</term>
<term>Microscopy, Fluorescence</term>
<term>Molecular Sequence Data</term>
<term>Peptide Fragments (analysis)</term>
<term>Peptide Fragments (metabolism)</term>
<term>Peptide Library</term>
<term>Prostate (chemistry)</term>
<term>Prostate (metabolism)</term>
<term>Prostate (pathology)</term>
<term>Prostate-Specific Antigen (chemistry)</term>
<term>Prostate-Specific Antigen (genetics)</term>
<term>Prostate-Specific Antigen (metabolism)</term>
<term>Prostatic Neoplasms (chemistry)</term>
<term>Prostatic Neoplasms (genetics)</term>
<term>Prostatic Neoplasms (metabolism)</term>
<term>Prostatic Neoplasms (pathology)</term>
<term>Protein Binding</term>
<term>Sequence Analysis, DNA</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Analyse de séquence d'ADN</term>
<term>Antigène spécifique de la prostate ()</term>
<term>Antigène spécifique de la prostate (génétique)</term>
<term>Antigène spécifique de la prostate (métabolisme)</term>
<term>Banque de peptides</term>
<term>Données de séquences moléculaires</term>
<term>Expression des gènes</term>
<term>Fluorescéines</term>
<term>Fragments peptidiques (analyse)</term>
<term>Fragments peptidiques (métabolisme)</term>
<term>Humains</term>
<term>Kallicréines ()</term>
<term>Kallicréines (génétique)</term>
<term>Kallicréines (métabolisme)</term>
<term>Liaison aux protéines</term>
<term>Ligands</term>
<term>Lignée cellulaire tumorale</term>
<term>Marqueurs biologiques tumoraux ()</term>
<term>Marqueurs biologiques tumoraux (génétique)</term>
<term>Marqueurs biologiques tumoraux (métabolisme)</term>
<term>Microscopie de fluorescence</term>
<term>Mâle</term>
<term>Prostate ()</term>
<term>Prostate (anatomopathologie)</term>
<term>Prostate (métabolisme)</term>
<term>Protéines immobilisées ()</term>
<term>Protéines immobilisées (génétique)</term>
<term>Protéines immobilisées (métabolisme)</term>
<term>Sites de fixation</term>
<term>Séquence d'acides aminés</term>
<term>Tests de criblage à haut débit</term>
<term>Tumeurs de la prostate ()</term>
<term>Tumeurs de la prostate (anatomopathologie)</term>
<term>Tumeurs de la prostate (génétique)</term>
<term>Tumeurs de la prostate (métabolisme)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en">
<term>Peptide Fragments</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en">
<term>Biomarkers, Tumor</term>
<term>Immobilized Proteins</term>
<term>Kallikreins</term>
<term>Prostate-Specific Antigen</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en">
<term>Biomarkers, Tumor</term>
<term>Immobilized Proteins</term>
<term>Kallikreins</term>
<term>Prostate-Specific Antigen</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Biomarkers, Tumor</term>
<term>Immobilized Proteins</term>
<term>Kallikreins</term>
<term>Peptide Fragments</term>
<term>Prostate-Specific Antigen</term>
</keywords>
<keywords scheme="MESH" qualifier="analyse" xml:lang="fr">
<term>Fragments peptidiques</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr">
<term>Prostate</term>
<term>Tumeurs de la prostate</term>
</keywords>
<keywords scheme="MESH" qualifier="chemistry" xml:lang="en">
<term>Prostate</term>
<term>Prostatic Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en">
<term>Prostatic Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr">
<term>Antigène spécifique de la prostate</term>
<term>Kallicréines</term>
<term>Marqueurs biologiques tumoraux</term>
<term>Protéines immobilisées</term>
<term>Tumeurs de la prostate</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>Prostate</term>
<term>Prostatic Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr">
<term>Antigène spécifique de la prostate</term>
<term>Fragments peptidiques</term>
<term>Kallicréines</term>
<term>Marqueurs biologiques tumoraux</term>
<term>Prostate</term>
<term>Protéines immobilisées</term>
<term>Tumeurs de la prostate</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en">
<term>Prostate</term>
<term>Prostatic Neoplasms</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Amino Acid Sequence</term>
<term>Binding Sites</term>
<term>Cell Line, Tumor</term>
<term>Fluoresceins</term>
<term>Gene Expression</term>
<term>High-Throughput Screening Assays</term>
<term>Humans</term>
<term>Ligands</term>
<term>Male</term>
<term>Microscopy, Fluorescence</term>
<term>Molecular Sequence Data</term>
<term>Peptide Library</term>
<term>Protein Binding</term>
<term>Sequence Analysis, DNA</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Analyse de séquence d'ADN</term>
<term>Antigène spécifique de la prostate</term>
<term>Banque de peptides</term>
<term>Données de séquences moléculaires</term>
<term>Expression des gènes</term>
<term>Fluorescéines</term>
<term>Humains</term>
<term>Kallicréines</term>
<term>Liaison aux protéines</term>
<term>Ligands</term>
<term>Lignée cellulaire tumorale</term>
<term>Marqueurs biologiques tumoraux</term>
<term>Microscopie de fluorescence</term>
<term>Mâle</term>
<term>Prostate</term>
<term>Protéines immobilisées</term>
<term>Sites de fixation</term>
<term>Séquence d'acides aminés</term>
<term>Tests de criblage à haut débit</term>
<term>Tumeurs de la prostate</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">The aim of this study was to identify potential ligands of PSMA suitable for further development as novel PSMA-targeted peptides using phage display technology. The human PSMA protein was immobilized as a target followed by incubation with a 15-mer phage display random peptide library. After one round of prescreening and two rounds of screening, high-stringency screening at the third round of panning was performed to identify the highest affinity binders. Phages which had a specific binding activity to PSMA in human prostate cancer cells were isolated and the DNA corresponding to the 15-mers were sequenced to provide three consensus sequences: GDHSPFT, SHFSVGS and EVPRLSLLAVFL as well as other sequences that did not display consensus. Two of the peptide sequences deduced from DNA sequencing of binding phages, SHSFSVGSGDHSPFT and GRFLTGGTGRLLRIS were labeled with 5-carboxyfluorescein and shown to bind and co-internalize with PSMA on human prostate cancer cells by fluorescence microscopy. The high stringency requirements yielded peptides with affinities KD~1 µM or greater which are suitable starting points for affinity maturation. While these values were less than anticipated, the high stringency did yield peptide sequences that apparently bound to different surfaces on PSMA. These peptide sequences could be the basis for further development of peptides for prostate cancer tumor imaging and therapy.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">23935860</PMID>
<DateCompleted>
<Year>2014</Year>
<Month>03</Month>
<Day>05</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Electronic-Print">
<Journal>
<ISSN IssnType="Electronic">1932-6203</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>8</Volume>
<Issue>7</Issue>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>PloS one</Title>
<ISOAbbreviation>PLoS ONE</ISOAbbreviation>
</Journal>
<ArticleTitle>Evaluation of phage display discovered peptides as ligands for prostate-specific membrane antigen (PSMA).</ArticleTitle>
<Pagination>
<MedlinePgn>e68339</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0068339</ELocationID>
<Abstract>
<AbstractText>The aim of this study was to identify potential ligands of PSMA suitable for further development as novel PSMA-targeted peptides using phage display technology. The human PSMA protein was immobilized as a target followed by incubation with a 15-mer phage display random peptide library. After one round of prescreening and two rounds of screening, high-stringency screening at the third round of panning was performed to identify the highest affinity binders. Phages which had a specific binding activity to PSMA in human prostate cancer cells were isolated and the DNA corresponding to the 15-mers were sequenced to provide three consensus sequences: GDHSPFT, SHFSVGS and EVPRLSLLAVFL as well as other sequences that did not display consensus. Two of the peptide sequences deduced from DNA sequencing of binding phages, SHSFSVGSGDHSPFT and GRFLTGGTGRLLRIS were labeled with 5-carboxyfluorescein and shown to bind and co-internalize with PSMA on human prostate cancer cells by fluorescence microscopy. The high stringency requirements yielded peptides with affinities KD~1 µM or greater which are suitable starting points for affinity maturation. While these values were less than anticipated, the high stringency did yield peptide sequences that apparently bound to different surfaces on PSMA. These peptide sequences could be the basis for further development of peptides for prostate cancer tumor imaging and therapy.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Shen</LastName>
<ForeName>Duanwen</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Radiology, Washington University, St Louis, Missouri, United States of America.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Xie</LastName>
<ForeName>Fei</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Edwards</LastName>
<ForeName>W Barry</ForeName>
<Initials>WB</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>PLoS One</MedlineTA>
<NlmUniqueID>101285081</NlmUniqueID>
<ISSNLinking>1932-6203</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005452">Fluoresceins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D055767">Immobilized Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008024">Ligands</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019151">Peptide Library</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>76823-03-5</RegistryNumber>
<NameOfSubstance UI="C045132">4-carboxyfluorescein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.21.-</RegistryNumber>
<NameOfSubstance UI="D007610">Kallikreins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.21.-</RegistryNumber>
<NameOfSubstance UI="C549870">kallikrein-related peptidase 3, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.21.77</RegistryNumber>
<NameOfSubstance UI="D017430">Prostate-Specific Antigen</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005452" MajorTopicYN="N">Fluoresceins</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D057166" MajorTopicYN="N">High-Throughput Screening Assays</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D055767" MajorTopicYN="N">Immobilized Proteins</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007610" MajorTopicYN="N">Kallikreins</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008856" MajorTopicYN="N">Microscopy, Fluorescence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName>
<QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D019151" MajorTopicYN="Y">Peptide Library</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011467" MajorTopicYN="N">Prostate</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D017430" MajorTopicYN="N">Prostate-Specific Antigen</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D017422" MajorTopicYN="N">Sequence Analysis, DNA</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2013</Year>
<Month>01</Month>
<Day>24</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2013</Year>
<Month>05</Month>
<Day>28</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2013</Year>
<Month>8</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2013</Year>
<Month>8</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2014</Year>
<Month>3</Month>
<Day>7</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">23935860</ArticleId>
<ArticleId IdType="doi">10.1371/journal.pone.0068339</ArticleId>
<ArticleId IdType="pii">PONE-D-13-03639</ArticleId>
<ArticleId IdType="pmc">PMC3723849</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>J Clin Oncol. 2004 Jan 15;22(2):379-80; author reply 380-1</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14722051</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2001 Aug 15;61(16):6029-33</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11507047</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Urology. 2004 Feb;63(2):309-13; discussion 313-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14972478</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cancer Ther. 2004 May;3(5):597-603</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15141017</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2004 May 27;350(22):2239-46</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15163773</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Expert Rev Mol Diagn. 2004 Jul;4(4):513-26</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15225099</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2004 Jul 1;22(13):2522-31</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15173215</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Methods Enzymol. 1996;267:3-27</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8743307</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 1997 Sep 1;57(17):3629-34</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9288760</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 1998 Sep 15;58(18):4055-60</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9751609</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):5981-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15837926</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2005 Jul 20;23(21):4591-601</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15837970</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2005 Oct 15;11(20):7454-61</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16243819</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Imaging. 2005 Oct-Dec;4(4):448-62</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16285907</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4005-10</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16537476</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>EMBO J. 2006 Mar 22;25(6):1375-84</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16467855</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2006 Sep 15;66(18):9171-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16982760</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Neoplasia. 2006 Sep;8(9):772-80</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16984734</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>FEBS Lett. 2007 May 1;581(9):1793-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17416362</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2007 May 1;13(9):2707-13</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17473203</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Med Chem. 2008 Aug 14;51(15):4504-17</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18637669</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Med Chem. 2008 Dec 25;51(24):7933-43</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19053825</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biomol Screen. 2009 Mar;14(3):273-81</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19211782</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Angew Chem Int Ed Engl. 2009;48(27):4944-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19301344</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Bioorg Med Chem Lett. 2009 Jul 15;19(14):3866-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19380225</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2009 Sep 1;69(17):6932-40</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19706750</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biochem Biophys Res Commun. 2009 Dec 18;390(3):624-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19818734</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biomol Screen. 2010 Jan;15(1):62-71</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20008125</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nucleic Acids Res. 2010 Jan;38(2):e11</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19897549</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>PLoS One. 2010;5(5):e10728</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20502719</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Med Chem. 2010 Jul 22;53(14):5333-41</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20568777</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biomol Screen. 2010 Oct;15(9):1099-106</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20855563</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Prostate. 2011 Feb 15;71(3):281-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20809553</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cancer Ther. 2009 May;8(5):1239-49</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19435868</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Angew Chem Int Ed Engl. 2011 Sep 19;50(39):9167-70</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21861274</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2011 Dec 15;17(24):7645-53</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22042970</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncotarget. 2011 Dec;2(12):1244-53</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22207391</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Angew Chem Int Ed Engl. 2012 Feb 20;51(8):1890-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22271427</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Anal Chem. 2012 Mar 20;84(6):2776-83</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22339784</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2012 Aug 20;30(24):3020-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22802323</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Oncol Pract. 2012 Sep;8(5):315-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23277770</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 1999 Oct;5(10):2674-81</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10537328</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Res. 1999 Dec;9(4):271-80</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10628836</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Methods. 2001 Feb;23(2):169-78</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11181036</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Cell Biochem. 2004 Feb 15;91(3):528-39</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14755683</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>États-Unis</li>
</country>
<region>
<li>Missouri (État)</li>
</region>
</list>
<tree>
<noCountry>
<name sortKey="Edwards, W Barry" sort="Edwards, W Barry" uniqKey="Edwards W" first="W Barry" last="Edwards">W Barry Edwards</name>
<name sortKey="Xie, Fei" sort="Xie, Fei" uniqKey="Xie F" first="Fei" last="Xie">Fei Xie</name>
</noCountry>
<country name="États-Unis">
<region name="Missouri (État)">
<name sortKey="Shen, Duanwen" sort="Shen, Duanwen" uniqKey="Shen D" first="Duanwen" last="Shen">Duanwen Shen</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B48 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001B48 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:23935860
   |texte=   Evaluation of phage display discovered peptides as ligands for prostate-specific membrane antigen (PSMA).
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:23935860" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a MersV1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021